Payment overview · 2025
General Payments
$2,724.09
42 reported records · 12 companies
Healthcare provider profile · identity verified
Lisa Ferguson
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · TERRE HAUTE, IN · NPI 1548669831
Verified facts
What the public records show
CMS Open Payments records show Lisa Ferguson received $2,724.09 in general payments during 2025 across 42 reported records.
Boston Scientific Corporation accounted for 65.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Abrysvo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $1,784.09 | 65.5% | 14 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $296.77 | 10.9% | 8 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $158.71 | 5.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $156.61 | 5.8% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $95.47 | 3.5% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $66.92 | 2.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.74 | 1.9% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $32.89 | 1.2% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $24.78 | 0.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.52 | 0.8% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $19.75 | 0.7% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $16.84 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,629.67 | 38 |
| Travel and Lodging | $1,094.42 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $1,424.76 | 7 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $359.33 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $296.77 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $142.03 | 2 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $116.30 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $95.47 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $66.92 | 3 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $50.74 | 2 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $42.41 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $32.89 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 401 | 138 |
| Levothyroxine Sodium | Levothyroxine Sodium | 288 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 174 | 61 |
| Lisinopril | Lisinopril | 152 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 143 | 55 |
| Losartan Potassium | Losartan Potassium | 138 | 47 |
| Ezetimibe | Ezetimibe | 132 | 49 |
| Famotidine | Famotidine | 126 | 43 |
| Gabapentin | Gabapentin | 122 | 43 |
| Allopurinol | Allopurinol | 97 | 26 |
| Metformin Hcl Er | Metformin Hcl | 96 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 93 | 40 |
| Omeprazole | Omeprazole | 92 | 34 |
| Sertraline Hcl | Sertraline Hcl | 83 | 26 |
| Farxiga | Dapagliflozin Propanediol | 80 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 80 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 24 |
| Mounjaro | Tirzepatide | 69 | 11 |
| Alendronate Sodium | Alendronate Sodium | 66 | 23 |
| Trazodone Hcl | Trazodone Hcl | 66 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 19 |
| Montelukast Sodium | Montelukast Sodium | 55 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 54 | 13 |
| Metformin Hcl | Metformin Hcl | 51 | 20 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 48 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | 18 |
| Alprazolam | Alprazolam | 43 | 13 |
| Tramadol Hcl | Tramadol Hcl | 40 | suppressed |
| Potassium Chloride | Potassium Chloride | 39 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 24 |
| Azithromycin | Azithromycin | 35 | 32 |
| Vascepa | Icosapent Ethyl | 35 | suppressed |
| Simvastatin | Simvastatin | 34 | 11 |
| Furosemide | Furosemide | 33 | 18 |
| Prednisone | Prednisone | 33 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | 11 |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Ozempic | Semaglutide | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 24 | 24 |
| Fluconazole | Fluconazole | 24 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Carvedilol | Carvedilol | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Repatha Syringe | Evolocumab | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 15 |
| Temazepam | Temazepam | 16 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,724.09 · 42 records | Boston Scientific Corporation | Assure WCD, CARDIOMEMS, FUROSCIX, JARDIANCE, Kerendia, LEQVIO, LifeVest, MITRACLIP, OPSUMIT, OPSYNVI, Ozempic, Rybelsus, UPTRAVI, VERQUVO, VYNDAQEL, WATCHMAN, WATCHMAN FLX, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error